4.4 Article

Injection drug use cessation and use of North America's first medically supervised safer injecting facility

Journal

DRUG AND ALCOHOL DEPENDENCE
Volume 113, Issue 2-3, Pages 172-176

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.drugalcdep.2010.07.023

Keywords

Injection drug use; Supervised injection; Injection cessation; Addiction treatment; Aboriginal ancestry

Funding

  1. Health Canada
  2. Canadian Institutes of Health Research (CIHR)
  3. Vancouver Coastal Health
  4. Michael Smith Foundation for Health Research
  5. National Institute of Drug Abuse, US National Institutes of Health [DP1DA026182]
  6. Abbott
  7. Argos Therapeutics
  8. Bioject Inc
  9. Boehringer Ingelheim
  10. BMS
  11. Gilead Sciences
  12. GlaxoSmithKline
  13. Hoffmann-La Roche
  14. Janssen-Ortho
  15. Merck Frosst
  16. Pfizer
  17. Schering
  18. Serono Inc
  19. TheraTechnologies
  20. Tibotec
  21. Trimeris

Ask authors/readers for more resources

Background: Vancouver, Canada has a pilot supervised injecting facility (SIF), where individuals can inject pre-obtained drugs under the supervision of medical staff. There has been concern that the program may facilitate ongoing drug use and delay entry into addiction treatment. Methods: We used Cox regression to examine factors associated with the time to the cessation of injecting, for a minimum of 6 months, among a random sample of individuals recruited from within the Vancouver SIF. In further analyses, we evaluated the time to enrolment in addiction treatment. Results: Between December 2003 and June 2006, 1090 participants were recruited. In Cox regression, factors independently associated with drug use cessation included use of methadone maintenance therapy (Adjusted Hazard Ratio [AHR] = 1.57 [95% Confidence Interval [CI]: 1.02-2.40]) and other addiction treatment (AHR = 1.85 [95% CI: 1.06-3.24]). In subsequent analyses, factors independently associated with the initiation of addiction treatment included: regular SIF use at baseline (AHR = 1.33 [95% CI: 1.04-1.72]): having contact with the addiction counselor within the SIF (AHR = 1.54 [95% CI: 1.13-2.08]): and Aboriginal ancestry (AHR = 0.66 [95% CI: 0.47-0.92]). Conclusions: While the role of addiction treatment in promoting injection cessation has been well described, these data indicate a potential role of SIF in promoting increased uptake of addiction treatment and subsequent injection cessation. The finding that Aboriginal persons were less likely to enroll in addiction treatment is consistent with prior reports and demonstrates the need for novel and culturally appropriate drug treatment approaches for this population. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available